Moskaliuk Vasyl, Balaniuk Iryna, Sorokhan Vasyl

OPTIMIZING TREATMENT OF PATIENTS WITH AIDS BY ADDING PROBIOTIC ENTEROL-250 TO HAART

Bukovinian State Medical University (Chernivtsi, Ukraine)

The purpose of the study. To study the effect of probiotic Enterol-250 alone or, if necessary, in combination with HAART on status of intestine microbiota of patients with AIDS.

Methods of the study: bacteriological, instrumental and statistical.

Study results. After a course of treatment with a probiotic Enterol-250, which was administered 2 capsules twice a day for 30 days alone or in combination with HAART to 82 patients with AIDS, noted a statistically significant decrease in clinical symptoms of dysbiosis.

Influenced proven treatment significantly changed intestine microbiota: under the influence of treatment Enterol-250 alone or in combination with HAART significantly improved qualitative and quantitative composition of microflora in the colon, which is statistically different from weighty indicators of microbial landscape of patients who received HAART along with symptomatic drug imodium or not receiving drug treatment (P <0,001).

According to the bacteriological data, under the influence of Enterol-250 treatment marked a significant reduction in the frequency allocation of pathogenic microorganisms. Drug was highly effective in staphylococcal, streptococcal and klebsiellal forms of dysbiosis.

Analysis of the microbiota of the colon after the 30-day course of treatment with Enterol-250 found that a change of the quantitative and qualitative composition of microflora was eliminated in 24,1% of individuals, and dysbiosis IV degree - complete elimination (both P <0,001). At the same time, the combination of Imodium with HAART had no significant effect on dysbiosis colon compared with HIV-infected who did not receive any treatment.

These data indicate the feasibility of repeated courses of probiotic Enterol-250 alone or, if necessary, in combination with HAART for normalization of intestine microbiota of patients with AIDS.

Found that the resulting of 30-days treatment with Enterol-250 only in 40,7% of patients with AIDS the rectoromanoscopic pattern was normalized. This was significantly higher than the frequency of the absence of morphological signs of inflammation of the terminal part of the intestine to treatment (P <0,001). In any patient who received this probiotic, showed no ulcerative inflammation of the mucosa of the terminal intestine (P <0,05).

Conclusions: Enterol-250 does not provide significant impact on the morphological signs of inflammation of the terminal part of the intestine. Along with the fact that the use Enterol-250 is not accompanied by the appearance of undesirable side reactions, confirmed the ability of this probiotic quickly, between 5-8 days, remove diarrheal HAART adverse reactions: nausea, recurrent abdominal pain, diarrhea, flatulence.